Protagonist has also received written comments from the
Based on the feedback from the FDA and EMA, Protagonist intends to initiate a global Phase 3 clinical trial of rusfertide in PV. The Phase 3 trial will be a randomized, placebo-controlled study of about 200 to 250 adult participants, including both high-risk and low-risk patients, who require frequent phlebotomy treatments with or without cytoreductive or other concomitant therapies. The primary endpoint will be the proportion of patients achieving a response, with response defined as absence of phlebotomy eligibility based on hematocrit control between weeks 20 through 32. In addition, there will a durability follow-up during weeks 32-52 of the study, after which participants will be offered open-label treatment for evaluation of long-term effects and safety. Frequency of phlebotomies, as well as symptom improvement as measured by MPN-TSS criteria, will be among the important secondary endpoints in the study.
'Rusfertide presents a unique potential treatment for the wide range of PV patients whose hematocrit remains uncontrolled by frequent phlebotomy-with or without cytoreductive agents-which thereby exposes them to significant thrombotic risks,' said Srdan Verstovsek, MD, PhD, an investigator on the Phase 2 study of rusfertide in PV and Professor in the
'We are very thankful to the FDA and EMA for their expedited dialogue around this potential new treatment for PV, and we look forward to advancing our clinical development program for rusfertide based on the clear and timely guidance these regulators have provided us,' said
About
About Polycythemia Vera
Polycythemia vera is a myeloproliferative neoplasm characterized primarily by the increased production of red blood cells. Well-established treatment guidelines focus on maintaining hematocrit levels continuously below 45 percent to reduce the risk of thrombotic events. Unfortunately, current treatment options are unable to maintain hematocrit to below the 45 percent target for many patients and may be associated with serious side effects. The prevalence of polycythemia vera is approximately 44 to 57 patients per 100,000 people in the
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding our intentions or current expectations concerning, among other things, our plans to conduct a Phase 3 trial evaluating rusfertide for PV. In some cases, you can identify these statements by forward-looking words such as 'anticipate,' 'believe,' 'may,' 'will,' 'expect,' or the negative or plural of these words or similar expressions. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, our ability to develop and commercialize our product candidates, our ability to earn milestone payments under our collaboration agreement with Janssen, the impact of the current COVID-19 pandemic on our discovery and development efforts, our ability to use and expand our programs to build a pipeline of product candidates, our ability to obtain and maintain regulatory approval of our product candidates, our ability to operate in a competitive industry and compete successfully against competitors that have greater resources than we do, and our ability to obtain and adequately protect intellectual property rights for our product candidates. Additional information concerning these and other risk factors affecting our business can be found in our periodic filings with the
Contact:
Tel: +1.510.474.0170
Email: j.taylor@pgtx-inc.com
(C) 2021 Electronic News Publishing, source